indazoles has been researched along with Parkinson Disease, Secondary in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Deng, J; Gao, C; Huo, C; Li, G; Li, GB; Li, YZ; Luo, ZY; Ning, XL; Peng, C; Qian, S; Ren, YL; Wang, M; Wang, SY; Wang, ZY; Wu, Y; Wu, YX; Yang, LL; Yu, JL; Zhu, KR | 1 |
| Campuzano, CM; Echeverry, MB; Fernandez-Villalba, E; Gomez, A; Herrero, MT; Ros, CM; Ros-Bernal, F; Yuste, JE | 1 |
| Beal, MF; Brouillet, E; Dolan, R; Ferrante, R; Hantraye, P; Matthews, RT; Palfi, S | 1 |
| Di Monte, DA; Jakowec, MW; Langston, JW; Royland, JE | 1 |
| Boireau, A; Bordier, F; Dubedat, P; Imperato, A; Moussaoui, S | 1 |
5 other study(ies) available for indazoles and Parkinson Disease, Secondary
| Article | Year |
|---|---|
X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Line, Tumor; Crystallography, X-Ray; Enzyme Inhibitors; Humans; Indazoles; Indoleamine-Pyrrole 2,3,-Dioxygenase; Male; Mice, Inbred C57BL; Molecular Docking Simulation; Molecular Structure; Neuroprotective Agents; Parkinson Disease, Secondary; Protein Binding; Structure-Activity Relationship; Tryptophan Oxygenase | 2021 |
7-Nitroindazole down-regulates dopamine/DARPP-32 signaling in neostriatal neurons in a rat model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Enzyme Inhibitors; Indazoles; Male; Neostriatum; Neurons; Nitric Oxide Synthase Type I; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Rats; Rats, Sprague-Dawley; Signal Transduction | 2012 |
Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Models, Animal; Dopamine; Enzyme Inhibitors; Homovanillic Acid; Hypokinesia; Indazoles; Male; Motor Activity; Neurologic Examination; Neurons; Nitric Oxide Synthase; Papio; Parkinson Disease, Secondary; Substantia Nigra; Videotape Recording | 1996 |
Role of nitric oxide in methamphetamine neurotoxicity: protection by 7-nitroindazole, an inhibitor of neuronal nitric oxide synthase.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Body Temperature; Dopamine Agents; Enzyme Inhibitors; Homovanillic Acid; Indazoles; Male; Methamphetamine; Mice; Neostriatum; Neuroprotective Agents; Neurotoxins; Nitric Oxide; Nitric Oxide Synthase; Parkinson Disease, Secondary; Tyrosine 3-Monooxygenase | 1996 |
The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Indazoles; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Parkinson Disease, Secondary; Riluzole | 2000 |